Department of Oral Pathology and Microbiology, Institute of Dental Sciences, Siksha O Anusandhan University, Bhubaneswar, Odisha, India.
General Dental Practitioner, Odisha, 757001, India.
F1000Res. 2024 May 31;13:557. doi: 10.12688/f1000research.149861.1. eCollection 2024.
Differentiating between ameloblastoma (AB) and ameloblastic carcinoma (AC) is difficult, especially when AB has atypical cytological characteristics or an uncommon clinical history. This systematic review and meta-analysis aimed to elucidate the differential expression of immunohistochemical markers between AB and AC.
We conducted a thorough search of PUBMED and SCOPUS according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify cross-sectional studies that compared the expression of immunohistochemical markers in AB and AC. We used a random-effects model to analyze the risk ratios and their corresponding 95% confidence intervals (CIs). The quality of the included studies was assessed using the Newcastle-Ottawa scale. The Egger's test was used to assess publication bias.
In total, 301 articles were identified. After excluding irrelevant titles and abstracts, 86 articles were selected for full-text review. We categorized the 41 markers into proliferative and non-proliferative markers. Among non-proliferative markers, nuclear markers were differentially expressed in AB and AC. SOX2 was the only marker that significantly differentiated AB and AC, with an RR of -0.19 (CI 0.10-0.36, I2=0).
The current evidence suggests the significance of SOX2 in differentiating between AB and AC, warranting prospective confirmation in well-defined extensive studies. We highlight the paucity of high-quality replicated studies of other markers in this field. Collaborative efforts with standardized techniques are necessary to generate clinically useful immunohistochemical markers.
区分造釉细胞瘤（AB）和造釉细胞癌（AC）具有一定难度，尤其是当 AB 具有非典型细胞学特征或不常见的临床病史时。本系统评价和荟萃分析旨在阐明 AB 和 AC 之间免疫组织化学标志物的差异表达。
我们根据系统评价和荟萃分析的首选报告项目（PRISMA）指南，对 PUBMED 和 SCOPUS 进行了全面检索，以确定比较 AB 和 AC 中免疫组织化学标志物表达的横断面研究。我们使用随机效应模型分析风险比及其相应的 95%置信区间（CI）。使用纽卡斯尔-渥太华量表评估纳入研究的质量。使用 Egger 检验评估发表偏倚。
共确定了 301 篇文章。在排除不相关的标题和摘要后，有 86 篇文章被选入全文审查。我们将 41 种标记物分为增殖性和非增殖性标记物。在非增殖性标志物中，核标志物在 AB 和 AC 中存在差异表达。SOX2 是唯一能显著区分 AB 和 AC 的标志物，其 RR 为-0.19（CI 0.10-0.36，I2=0）。
目前的证据表明 SOX2 在区分 AB 和 AC 方面具有重要意义，值得在定义明确的广泛研究中进一步确认。我们强调在该领域其他标志物的高质量复制研究相对较少。需要进行协作努力，采用标准化技术来生成具有临床应用价值的免疫组织化学标志物。
